In case of chronic myeloid leukemia (CML), the BCR-ABL gene fusion is the major disease driver, and treatment involves use of tyrosine kinase inhibitor (TKI), causing remission in the vast majority of the cases. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.